Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by investclubon Feb 01, 2020 8:17pm

186 Views

Post# 30630008

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA IND NEWS!!!!!!!!!!!!!!!!!!

Hi enriquesuave
Glad to see your comment Friday afternoon I went to a hospital to visit a friend who suffered a fine crack in her pelvis from a fall while vacationing in Jamaica which was more embarrassing then anything. So her daughter works at the clinical research facility mostly on breast cancer trials that they do for large pharma. Her daughter was visiting when I got there and she is very familiar with TLT because of me. So we discussed the trial and she said the very large hospital she worked in would need to purchase all the equipment if they were to eventually treat patients with the Theralase procedure. Now correct me if I'm wrong I told her 'no' much of the equipment you already have I said you will only have to buy the TLD-3200 (as you stated). Will hospitals need very new monitors and or special technology that is compatible to the TLD-3200?

enriquesuave wrote

The procedure is actually quite simple and requires minimal training IMO. TLD-1433 is instilled like BCG. A standard flexible cystoscope is used in which the fibre optic cable (DFOC) is simply inserted thru the working channel of the cystoscope. Light is switched on and the TLD-3200 system allerts the Urologist when the correct amount of light energy has been delivered. It does require training but simply in the steps involved. Every aspect of the treatment involves routinely used equipment and procedures with the only exception of the fibre optic cable and use of the new TLD-3200 system. This is not like learning a new surgical technique which requires practice,IMO after seeing one procedure and learning the steps, there is no reason for technique not to be mastered. All IMO. Dr Jewett explains this well in the AGM meeting video.

Hempdoc wrote:

Quattro74 wrote:
Having that TMO agreement in the US should mean a rapid start, once IND is approved. :-)

The TMO was a necessity & should help tremendously. This treatment is definitely not your norm & certainly requires a lot more training-time than your standard & more familiar chemo/immunotherapy protocols. However, I'm not certain academic centers or other trial sites would commit their time/resources to training when a trial is on a clinical hold...unless the deficiencies are unrelated to the actual procedure? Comments would be much appreciated.